Caris Life Sciences, Inc. (CAI) Balance Sheet
CAI balance sheet, 2025
December 31, 2025 · U.S. dollars$1.13B assets = $548.4M liabilities + $577.3M equity
Both columns are drawn to the same scale: what CAI owns equals what it owes plus shareholders’ equity. Hover a block for its value.
CAI financial health
Descriptive bands, not a rating. Fiscal 2025.
CAI balance sheet trends, 2015–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $1.99B2015 | $1.13B2025 | −6.1%/yr | |
| Total liabilities | $1.53B2015 | $548.4M2025 | −10.7%/yr | |
| Shareholders’ equity | $460.3M2015 | $577.3M2025 | +2.5%/yr | |
| Cash & short-term investments | $73.7M2015 | $800.1M2025 | +30.3%/yr | |
| Total debt | $1.43B2015 | $379.0M2025 | −13.7%/yr | |
| Net cash (debt) | −$1.36B2015 | $421.1M2025 | +$1.8B | |
| Working capital | −$73.8M2015 | $870.7M2025 | +$944.4M | |
| Book value per share | −$6.682022 | $1.992025 | — | |
| Current ratio | 0.662015 | 7.852025 | +7.19 | |
| Debt / equity | 3.112015 | 0.662025 | −2.45 | |
| Shares outstanding | 254.8M2022 | 289.9M2025 | +4.4%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CAI assets
CAI liabilities and equity
CAI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
CAI balance sheet
| 2025 | 2024 | 2023 | 2022 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $800.1M | $66.2M | $121.6M | $409.6M | $132.5M | $46.5M | $121.3M | $65.5M | $66.1M | $73.7M |
| Cash & equivalents | $797.8M | $64.0M | $56.4M | $107.2M | $53.5M | $46.5M | $45.3M | $35.4M | $46.1M | $52.6M |
| Short-term investments | $2.3M | $2.2M | $65.2M | $302.4M | $79.0M | — | $76.0M | $30.1M | $20.0M | $21.2M |
| Receivables | $112.1M | $88.2M | $55.3M | $40.2M | $144.3M | $159.7M | $171.9M | $100.7M | $83.7M | $76.4M |
| Inventory | $63.6M | $39.6M | $49.0M | $47.0M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $21.9M | $21.8M | $16.7M | $19.2M | $0 | $293.0M | $0 | $0 | $0 | $0 |
| Total current assets | $997.8M | $215.7M | $242.6M | $516.0M | $214.7M | $499.1M | $220.0M | $140.3M | $135.2M | $144.1M |
| Property, plant & equipment (net) | $63.2M | $102.8M | $147.5M | $138.0M | $1.78B | $1.82B | $2.27B | $2.01B | $1.81B | $1.75B |
| Goodwill & intangible assets | $19.3M | $19.3M | $19.3M | $19.3M | $0 | $19.9M | $21.5M | $23.5M | $25.5M | $4.1M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $45.3M | $5.9M | $3.4M | $44.0M | $616.6M | $562.0M | $504.8M | $261.2M | $87.7M | $89.4M |
| Total assets | $1.13B | $343.7M | $412.9M | $717.4M | $2.61B | $2.90B | $3.01B | $2.43B | $2.06B | $1.99B |
| Liabilities | ||||||||||
| Accounts payable | $39.2M | $27.8M | $26.7M | $27.3M | $3.7M | $7.3M | $7.4M | $7.8M | $13.8M | $12.0M |
| Short-term debt | $169,000 | $66.2M | $6.8M | $57.1M | $183.4M | $218.1M | $311.4M | $132.0M | $95.5M | $172.4M |
| Deferred revenue | — | $7.5M | $5.7M | $1.4M | $3.0M | $6.4M | $7.6M | $7.8M | $10.6M | $12.0M |
| Total current liabilities | $127.1M | $165.4M | $95.1M | $136.9M | $320.2M | $287.4M | $425.5M | $259.9M | $164.0M | $217.9M |
| Long-term debt | $378.4M | $319.2M | $166.1M | $169.6M | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $49.2M | $45.1M | $51.0M | $48.5M | — | — | — | — | — | — |
| Other long-term liabilities | $42.8M | $2.36B | $2.30B | $2.11B | $1.59B | $1.92B | $1.89B | $1.61B | $1.43B | $1.31B |
| Total liabilities | $548.4M | $2.84B | $2.56B | $2.42B | $1.91B | $2.21B | $2.31B | $1.87B | $1.60B | $1.53B |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $283,000 | $38,000 | $38,000 | $138,000 | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 |
| Retained earnings (deficit) | −$2.55B | −$2.47B | −$2.12B | −$1.68B | $503.3M | $493.3M | $471.1M | $397.6M | $324.6M | $319.7M |
| Accumulated other comprehensive income | $936,000 | $210,000 | $218,000 | $1.7M | −$5.7M | −$6.6M | −$6.5M | −$6.1M | −$8.1M | −$7.9M |
| Total shareholders' equity | $577.3M | −$2.50B | −$2.14B | −$1.70B | $702.2M | $693.2M | $701.1M | $563.8M | $457.5M | $460.3M |
| Key figures | ||||||||||
| Total debt | $379.0M | $424.3M | $217.3M | $270.9M | $1.75B | $2.10B | $2.16B | $1.70B | $1.48B | $1.43B |
| Net cash (debt) | $421.1M | −$358.1M | −$95.7M | $138.8M | −$1.61B | −$2.05B | −$2.04B | −$1.64B | −$1.41B | −$1.36B |
| Working capital | $870.7M | $50.3M | $147.5M | $379.1M | −$105.6M | $211.7M | −$205.5M | −$119.6M | −$28.9M | −$73.8M |
| Tangible book value | $558.0M | −$2.52B | −$2.16B | −$1.72B | $702.2M | $673.3M | $679.6M | $540.3M | $432.0M | $456.2M |
| Book value per share | $1.99 | −$9.81 | −$8.42 | −$6.68 | — | — | — | — | — | — |
| Shares outstanding | 289.9M | 254.7M | 254.7M | 254.8M | — | — | — | — | — | — |
| Current ratio | 7.85 | 1.30 | 2.55 | 3.77 | 0.67 | 1.74 | 0.52 | 0.54 | 0.82 | 0.66 |
| Quick ratio | 7.17 | 0.93 | 1.86 | 3.29 | 0.86 | 0.72 | 0.69 | 0.64 | 0.91 | 0.69 |
| Debt / equity | 0.66 | — | — | — | 2.49 | 3.03 | 3.08 | 3.02 | 3.23 | 3.11 |
| Equity / assets | 51.3% | −727.0% | −519.5% | −237.3% | 26.9% | 23.9% | 23.3% | 23.2% | 22.3% | 23.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '21 | Jun '21 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & short-term investments | $793.1M | $823.5M | $800.1M | $755.5M | $721.2M | $33.4M | $66.2M | $47.0M | $38.8M |
| Cash & equivalents | $690.9M | $821.1M | $797.8M | $753.2M | $718.9M | $31.2M | $64.0M | $47.0M | $38.8M |
| Short-term investments | $102.2M | $2.3M | $2.3M | $2.3M | $2.2M | $2.2M | $2.2M | — | — |
| Receivables | $116.9M | $90.5M | $112.1M | $26.7M | $50.9M | $80.2M | $88.2M | $190.8M | $166.1M |
| Inventory | $123.8M | $76.3M | $63.6M | $49.3M | $40.6M | $36.6M | $39.6M | $0 | $0 |
| Other current assets | $24.0M | $23.9M | $21.9M | $22.8M | $20.6M | $21.1M | $21.8M | $4.8M | $6.0M |
| Total current assets | $1.06B | $1.01B | $997.8M | $854.2M | $833.3M | $171.2M | $215.7M | $242.6M | $210.9M |
| Property, plant & equipment (net) | $95.7M | $82.7M | $63.2M | $64.0M | $61.3M | $61.7M | $102.8M | $2.17B | $1.94B |
| Goodwill & intangible assets | $19.3M | $19.3M | $19.3M | $19.3M | $19.3M | $19.3M | $19.3M | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $56.7M | $46.2M | $45.3M | $47.0M | $41.1M | $39.4M | $5.9M | $851.9M | $800.2M |
| Total assets | $1.23B | $1.16B | $1.13B | $984.6M | $955.1M | $291.6M | $343.7M | $3.27B | $2.96B |
| Liabilities | |||||||||
| Accounts payable | $86.0M | $69.8M | $39.2M | $29.0M | $28.7M | $24.2M | $27.8M | $3.4M | $4.4M |
| Short-term debt | $6.5M | $6.0M | $169,000 | $6.6M | $7.4M | $66.1M | $66.2M | $161.7M | $116.4M |
| Deferred revenue | $20.5M | — | — | — | $5.3M | $7.7M | — | $9.7M | $2.4M |
| Total current liabilities | $191.4M | $143.9M | $127.1M | $86.0M | $90.2M | $162.6M | $165.4M | $338.5M | $467.0M |
| Long-term debt | $393.0M | $381.4M | $378.4M | $376.3M | $373.6M | $316.6M | $0 | $0 | $0 |
| Lease obligations | $59.3M | $49.4M | $49.2M | $50.3M | $45.3M | $43.1M | — | — | — |
| Other long-term liabilities | $53.5M | $43.6M | $42.8M | $43.9M | $38.4M | $2.41B | $455.5M | $2.13B | $1.73B |
| Total liabilities | $637.9M | $568.9M | $548.4M | $506.2M | $502.2M | $2.89B | $620.9M | $2.47B | $2.20B |
| Shareholders' equity | |||||||||
| Common stock & paid-in capital | $283,000 | $284,000 | $283,000 | $283,000 | $282,000 | $38,000 | $38,000 | $2,000 | $2,000 |
| Retained earnings (deficit) | −$2.55B | −$2.55B | −$2.55B | −$2.63B | −$2.66B | −$2.58B | −$2.47B | $605.9M | $562.2M |
| Accumulated other comprehensive income | $529,000 | $893,000 | $936,000 | $748,000 | $669,000 | $245,000 | −$26.2M | $175,000 | $96,000 |
| Total shareholders' equity | $591.7M | $593.5M | $577.3M | $478.4M | $452.9M | −$2.60B | −$277.2M | $800.7M | $756.3M |
| Key figures | |||||||||
| Total debt | $452.4M | $431.0M | $379.0M | $426.7M | $419.0M | $419.8M | $424.3M | $2.26B | $1.82B |
| Net cash (debt) | $340.7M | $392.5M | $421.1M | $328.8M | $302.2M | −$386.4M | −$358.1M | −$2.21B | −$1.78B |
| Working capital | $866.4M | $870.3M | $870.7M | $768.2M | $743.1M | $8.7M | $50.3M | −$95.9M | −$256.1M |
| Tangible book value | $572.4M | $574.1M | $558.0M | $459.0M | $433.6M | −$2.62B | −$296.5M | $800.7M | $756.3M |
| Book value per share | $2.09 | $2.10 | $1.99 | $1.61 | $1.64 | −$10.20 | −$0.99 | — | — |
| Shares outstanding | 282.9M | 282.6M | 289.9M | 297.2M | 276.0M | 254.8M | 281.1M | — | — |
| Current ratio | 5.53 | 7.05 | 7.85 | 9.93 | 9.24 | 1.05 | 1.30 | 0.72 | 0.45 |
| Quick ratio | 4.75 | 6.35 | 7.17 | 9.09 | 8.56 | 0.70 | 0.93 | 0.70 | 0.44 |
| Debt / equity | 0.76 | 0.73 | 0.66 | 0.89 | 0.93 | — | — | 2.82 | 2.41 |
| Equity / assets | 48.1% | 51.1% | 51.3% | 48.6% | 47.4% | −891.6% | −80.6% | 24.5% | 25.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 3, 2026); data from EODHD.
CAI financial position
At the end of fiscal 2025 (December 31, 2025), Caris Life Sciences had total assets of $1.1 billion (up 227.5% from a year earlier), total liabilities of $548.4 million and shareholders' equity of $577.3 million. It held $800.1 million in cash and short-term investments against $379.0 million of debt, a net cash position of $421.1 million. Its current ratio was 7.85. In the latest quarter (ended June 30, 2026) total assets were $1.2 billion and equity $591.7 million.
Related: CAI income statement, CAI cash flow statement, CAI key metrics. See the CAI stock overview for the latest quote and news.
CAI balance sheet FAQ
What are Caris Life Sciences's total assets?
Caris Life Sciences reported total assets of $1.1 billion at the end of fiscal 2025 (December 31, 2025), compared with $343.7 million a year earlier.
How much debt does Caris Life Sciences have?
Caris Life Sciences had $379.0 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.66.
How much cash does Caris Life Sciences have?
Caris Life Sciences held $800.1 million in cash and short-term investments at the end of fiscal 2025; with $379.0 million of debt that is net cash of $421.1 million.
What is Caris Life Sciences's book value?
Caris Life Sciences's shareholders' equity (book value) was $577.3 million at the end of fiscal 2025, or $1.99 per share.
What is Caris Life Sciences's current ratio?
Caris Life Sciences had current assets of $997.8 million and current liabilities of $127.1 million, a current ratio of 7.85 (it can cover its short-term obligations).
How much goodwill does Caris Life Sciences have?
Caris Life Sciences carried $19.3 million of goodwill and intangible assets, 1.7% of total assets, at the end of fiscal 2025.